Clinical Trial Update: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating multiple targeted therapies (capmatinib, ceritinib, regorafenib, or entrectinib) in patients with BRAF/NRAS wild-type s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Invasive Skin Melanoma
• Stage Iiia Cutaneous Melanoma
• Stage Iiib Cutaneous Melanoma
• Stage Iiic Cutaneous Melanoma

Drugs mentioned

• Capmatinib (capmatinib)
• Ceritinib (ceritinib)
• Entrectinib (entrectinib)
• Regorafenib (regorafenib)

Snippet

Sponsor: University of California, San Francisco | Conditions: ALK Fusion Protein Expression, BRAF wt Allele | Phase 2 | Status: TERMINATED | Results posted: 2020-01-27